KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Castle Biosciences (CSTL) Operating Expenses (2018 - 2026)

Castle Biosciences' Operating Expenses history spans 8 years, with the latest figure at $90.8 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 10.43% to $90.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $387.0 million, a 19.68% increase, with the full-year FY2025 number at $387.0 million, up 19.68% from a year prior.
  • Operating Expenses hit $90.8 million in Q4 2025 for Castle Biosciences, up from $89.8 million in the prior quarter.
  • Over the last five years, Operating Expenses for CSTL hit a ceiling of $115.9 million in Q1 2025 and a floor of $24.1 million in Q1 2021.
  • Historically, Operating Expenses has averaged $67.0 million across 5 years, with a median of $71.5 million in 2023.
  • Biggest five-year swings in Operating Expenses: soared 139.07% in 2021 and later grew 6.64% in 2024.
  • Tracing CSTL's Operating Expenses over 5 years: stood at $40.2 million in 2021, then skyrocketed by 52.13% to $61.2 million in 2022, then rose by 17.34% to $71.8 million in 2023, then grew by 14.6% to $82.3 million in 2024, then rose by 10.43% to $90.8 million in 2025.
  • Business Quant data shows Operating Expenses for CSTL at $90.8 million in Q4 2025, $89.8 million in Q3 2025, and $90.4 million in Q2 2025.